HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Tyligand Bioscience / Equity Capital Markets

<ul>
<li>The difficulty of developing KRAS G12D has been recognized by the industry. Investors will be more cautious about any early and unverified G12D projects, demanding higher risk premiums.</li>
<li>Without data validation, the market cannot assess whether the efficacy/safety of TSN1611 are competitive. The “good safety” data of TSN222 still needs to be validated through larger clinical trials.</li>
<li>We think Tyligand’s valuation may not exceed the valuations of comparable companies such as <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1167 HK)</a> and <a href="https://www.smartkarma.com/entities/genfleet-therapeutics" target="_blank" data-smartkarma-citation="entities:44187:1" rel="noopener">GenFleet Therapeutics (GENFL12 HK)</a>.</li>
</ul>


The difficulty of developing KRAS G12D has been recognized by the industry. Investors will be more cautious about any early and unverified G12D projects, demanding higher risk premiums.
Without data validation, the market cannot assess whether the efficacy/safety of TSN1611 are competitive. The “good safety” data of TSN222 still needs to be validated through larger clinical trials.
We think Tyligand’s valuation may not exceed the valuations of comparable companies such as Jacobio Pharmaceuticals (1167 HK) and GenFleet Therapeutics (GENFL12 HK).


Pre-IPO Tyligand Bioscience - Concerns on KRAS Will Directly Limit the Valuation Ceiling

Thematic (Sector/Industry)

Industry viewpoints:<ul>
<li>Last week, Biden’s administration surprised the whole pharmaceutical industry about the proposal to waive patent protections for coronavirus shots. However, our view is that the impact is likely to be limited.</li>
<li>The market size of COVID-19 vaccines in China is expected to reach RMB150 billion to RMB180 billion.</li>
<li>Recently, the National Health Care Security Administration, National Health Commission, NMPA and other related departments released documents about medium - and long-term development plan for the isotopes for medical purposes.</li>
</ul>Company news:News about the updated progress on new drugs of <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a>, <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1167 HK)</a>, <a href="https://www.smartkarma.com/entities/everest-medicines-ltd" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a> and <a href="https://www.smartkarma.com/entities/antengene-corp-ltd" target="_blank" data-smartkarma-citation="entities:29705:1" rel="noopener">Antengene (6996 HK).</a> Market review:Last week, stock price for healthcare sector in A share decreased 6.14%, while CSI 300 decreased 2.49% over the same period of time.Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Industry viewpoints:
Last week, Biden’s administration surprised the whole pharmaceutical industry about the proposal to waive patent protections for coronavirus shots. However, our view is that the impact is likely to be limited.
The market size of COVID-19 vaccines in China is expected to reach RMB150 billion to RMB180 billion.
Recently, the National Health Care Security Administration, National Health Commission, NMPA and other related departments released documents about medium - and long-term development plan for the isotopes for medical purposes.
Company news:News about the updated progress on new drugs of BeiGene Ltd (6160 HK), Jacobio Pharmaceuticals (1167 HK), Everest Medicines (1952 HK) and Antengene (6996 HK). Market review:Last week, stock price for healthcare sector in A share decreased 6.14%, while CSI 300 decreased 2.49% over the same period of time.Risk disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.  

1. Industry viewpoints:<ul>
<li>With the aggravation of aging, the number of stroke patients would grow rapidly and it is estimated that the potential market size of neurointerventional medical devices would reach RMB33.3 billion in 2025</li>
<li>China has a huge demographic dividend and demand for vision correction. It is expected to be a large growth space for orthokeratology lenses industry in China.</li>
<li>Pet medical industry started late in China, but it develops rapidly.</li>
</ul>2. Company news:News about the progress of new drugs of <a href="https://www.smartkarma.com/entities/everest-medicines" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a>, <a href="https://www.smartkarma.com/entities/antengene-corporation-limited" target="_blank" data-smartkarma-citation="entities:29705:1" rel="noopener">Antengene (6996 HK)</a> and <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1167 HK)</a>.3. Market review:Last week, stock price for healthcare sector in A share increased 2.88%, while CSI 300 increased 5.45% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
With the aggravation of aging, the number of stroke patients would grow rapidly and it is estimated that the potential market size of neurointerventional medical devices would reach RMB33.3 billion in 2025
China has a huge demographic dividend and demand for vision correction. It is expected to be a large growth space for orthokeratology lenses industry in China.
Pet medical industry started late in China, but it develops rapidly.
2. Company news:News about the progress of new drugs of Everest Medicines (1952 HK), Antengene (6996 HK) and Jacobio Pharmaceuticals (1167 HK).3. Market review:Last week, stock price for healthcare sector in A share increased 2.88%, while CSI 300 increased 5.45% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>HJ Science, a clinical-stage biotech company, has launched its HK IPO consisting of 14M H shares. The offer price has been fixed at HK$81.80 per share.</li>
<li>The company intends to raise HK$1,112M, primarily to fund ongoing and planned R&amp;D activities for pipeline products, mainly for the late-stage trials and registration of core product candidate HJ787.</li>
<li>The subscription period will close on June 17, 2026, with the shares expected to make trading debut on June 23, 2026. Citic Securities is the sole sponsor to the issue.</li>
</ul>


HJ Science, a clinical-stage biotech company, has launched its HK IPO consisting of 14M H shares. The offer price has been fixed at HK$81.80 per share.
The company intends to raise HK$1,112M, primarily to fund ongoing and planned R&amp;D activities for pipeline products, mainly for the late-stage trials and registration of core product candidate HJ787.
The subscription period will close on June 17, 2026, with the shares expected to make trading debut on June 23, 2026. Citic Securities is the sole sponsor to the issue.


HJ Science IPO: Late Move in Crowded Market Dampens Future Growth Prospect

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Mar 20th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Netease Cloud Music (9899 HK), Yidu Tech (2158 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Geely Automobile (175 HK), Netease Cloud Music (9899 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Mar 20th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Netease Cloud Music (9899 HK), Yidu Tech (2158 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Xiaomi (1810 HK), Geely Automobile (175 HK), Netease Cloud Music (9899 HK).


Hong Kong Buybacks Weekly (Mar 20th): Xiaomi, Netease Cloud Music, Yidu Tech

China

Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the in-house discovery and development of innovative oncology therapies, focusing on "undruggable" targets in key oncogenic pathways. They leverage their Induced Allosteric Molecule Discovery Platform and iADC Platform to develop novel drugs, including clinical-stage candidates like Glecirasib (KRAS G12C inhibitor) and Sitneprotafib (SHP2 inhibitor) for various solid tumors. The company was founded in 2015 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jacobio Pharmaceuticals (1167 HK)

Pre-IPO Tyligand Bioscience - Concerns on KRAS Will Directly Limit the Valuation Ceiling

Investors wary of early KRAS G12D projects, demand higher risk premiums. Validation needed for TSN1611 and TSN222. Tyligand's valuation may not...

Xinyao (Criss) Wang

China Healthcare Weekly (May.7)

The article analyzed the potential impact on Biden’s proposal to waive IP protection on COVID-19 shots,market size of COVID-19 vaccine,new...

Xinyao (Criss) Wang

China Healthcare Weekly (Jan.8)

The article analyzed the viewpoints in neurointerventional medical devices market, orthokeratology lenses market and pet medical market in China,...

Xinyao (Criss) Wang

HJ Science IPO: Late Move in Crowded Market Dampens Future Growth Prospect

HJ Science has launched its HK IPO consisting of 14M H shares at HK$81.80 per share to fund ongoing and planned R&D activities for pipeline...

Tina Banerjee

Hong Kong Buybacks Weekly (Mar 20th): Xiaomi, Netease Cloud Music, Yidu Tech

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Tyligand Bioscience - Concerns on KRAS Will Directly Limit the Valuation Ceiling

​Investors wary of early KRAS G12D projects, demand higher risk premiums. Validation needed for TSN1611 and TSN222. Tyligand's valuation may not...

Xinyao (Criss) Wang

China Healthcare Weekly (May.7)

The article analyzed the potential impact on Biden’s proposal to waive IP protection on COVID-19 shots,market size of COVID-19 vaccine,new...

Xinyao (Criss) Wang

China Healthcare Weekly (Jan.8)

The article analyzed the viewpoints in neurointerventional medical devices market, orthokeratology lenses market and pet medical market in China,...

Xinyao (Criss) Wang

HJ Science IPO: Late Move in Crowded Market Dampens Future Growth Prospect

HJ Science has launched its HK IPO consisting of 14M H shares at HK$81.80 per share to fund ongoing and planned R&D activities for pipeline...

Tina Banerjee

Hong Kong Buybacks Weekly (Mar 20th): Xiaomi, Netease Cloud Music, Yidu Tech

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Xiaomi (1810 HK),...

Ke Yan, CFA, FRM

Investors wary of early KRAS G12D projects, demand higher risk premiums. Validation needed for TSN1611 and TSN222. Tyligand's valuation may not...